{
  "resourceType": "ValueSet",
  "id": "informational-messages-codes",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This value set contains 242 concepts</p><p>All codes in this table are from the system <code>http://hcxprotocol.io/codes/informational-messages-codes</code></p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG045A\"> </a>  MG045A</td><td>Dialysis payable separately as an add on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG072A\"> </a>  MG072A</td><td>Package cost of one session</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG072B\"> </a>  MG072B</td><td>Package cost of one session</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG075A\"> </a>  MG075A</td><td>Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and  confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MG076A\"> </a>  MG076A</td><td>Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and  confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013A\"> </a>  MO013A</td><td>Stage II and III anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014F\"> </a>  MO014F</td><td>Neoadjuvant and adjuvant rectal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015B\"> </a>  MO015B</td><td>Upper esophageal  neoadjuvant and  with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A\"> </a>  MO062A</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062B\"> </a>  MO062B</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062C\"> </a>  MO062C</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068C\"> </a>  MO068C</td><td>NON-HODGKINS LYMPHOMA</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR001A\"> </a>  MR001A</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR001B\"> </a>  MR001B</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR001C\"> </a>  MR001C</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR004A\"> </a>  MR004A</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR004B\"> </a>  MR004B</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR004C\"> </a>  MR004C</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR006A\"> </a>  MR006A</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR006B\"> </a>  MR006B</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR006C\"> </a>  MR006C</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR009A\"> </a>  MR009A</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR009B\"> </a>  MR009B</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MR009C\"> </a>  MR009C</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma &amp; certain Bone Tumours`</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB030A\"> </a>  SB030A</td><td>Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032A\"> </a>  SB032A</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown &quot;For Rockwood Type I &amp; II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?&quot; \nFor Hospitals booking Surgical Correction in Type I &amp; Type II cases, Medical Audit will be conducted.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032B\"> </a>  SB032B</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown &quot;For Rockwood Type I &amp; II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?&quot; \nFor Hospitals booking Surgical Correction in Type I &amp; Type II cases, Medical Audit will be conducted.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032C\"> </a>  SB032C</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032D\"> </a>  SB032D</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032E\"> </a>  SB032E</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB032F\"> </a>  SB032F</td><td>Surgical Management for Type III &amp; IV Rockwood to be decided by the surgeon on case to case basis\nType V &amp; VI to be taken up for Surgery straight away</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SB070A\"> </a>  SB070A</td><td>LA for - K Wire &amp; Screw\nGA for - Nail &amp; Plate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SC076A\"> </a>  SC076A</td><td>If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012A\"> </a>  SE012A</td><td>The package is inclusive of Eye Bank processing fee</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE012B\"> </a>  SE012B</td><td>This is a special  follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE018A\"> </a>  SE018A</td><td>To be done only after a prior scleral buckling surgery history</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE022A\"> </a>  SE022A</td><td>Can be booked only after 1 year of cataract surgery</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE025A\"> </a>  SE025A</td><td>Can be booked as a complication of cataract surgery atleast 15 days after discharge</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029A\"> </a>  SE029A</td><td>The procedure is done only once per eye and not repeated</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE029B\"> </a>  SE029B</td><td>1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SE033A\"> </a>  SE033A</td><td>Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097A\"> </a>  SG097A</td><td>Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SG097B\"> </a>  SG097B</td><td>Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU052A\"> </a>  SU052A</td><td>Payment to be made after completion of one month.</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060A\"> </a>  SU060A</td><td>Claim to be raised after 6th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU060B\"> </a>  SU060B</td><td>Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071C\"> </a>  SU071C</td><td>No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SU071D\"> </a>  SU071D</td><td>The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-SV032A\"> </a>  SV032A</td><td>Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001A\"> </a>  MO001A</td><td>Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001B\"> </a>  MO001B</td><td>Adjuvant therapy after 4 cycles of AC or EC</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001C\"> </a>  MO001C</td><td>Metstatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001D\"> </a>  MO001D</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001E\"> </a>  MO001E</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001F\"> </a>  MO001F</td><td>Adjuvant therapy in breast cancer with Her-2 neu positive patients</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001G\"> </a>  MO001G</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001H\"> </a>  MO001H</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001I\"> </a>  MO001I</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001J\"> </a>  MO001J</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001K\"> </a>  MO001K</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001L\"> </a>  MO001L</td><td>Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001M\"> </a>  MO001M</td><td>Metastatic  breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001N\"> </a>  MO001N</td><td>Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO001O\"> </a>  MO001O</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO002A\"> </a>  MO002A</td><td>Metastatic bone malignancy and multiple myeloma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003A\"> </a>  MO003A</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003B\"> </a>  MO003B</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003C\"> </a>  MO003C</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003D\"> </a>  MO003D</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003E\"> </a>  MO003E</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003F\"> </a>  MO003F</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO003G\"> </a>  MO003G</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004A\"> </a>  MO004A</td><td>Testicular Seminoma, Adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004B\"> </a>  MO004B</td><td>Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004C\"> </a>  MO004C</td><td>Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004D\"> </a>  MO004D</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004E\"> </a>  MO004E</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004F\"> </a>  MO004F</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO004G\"> </a>  MO004G</td><td>Germ cell tumour second line therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005A\"> </a>  MO005A</td><td>First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005B\"> </a>  MO005B</td><td>First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO005C\"> </a>  MO005C</td><td>First line therapy for low risk Gestational Trophoblastic Neoplasia</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006A\"> </a>  MO006A</td><td>Neoadjuvant and metastatic Cervical Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO006B\"> </a>  MO006B</td><td>Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007A\"> </a>  MO007A</td><td>Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO007B\"> </a>  MO007B</td><td>Metastatic Endometrial Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008A\"> </a>  MO008A</td><td>NACT, mets</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO008B\"> </a>  MO008B</td><td>Stage II and Stage III cervical cancer definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO009A\"> </a>  MO009A</td><td>Ewing Sarcoma second line chemotherapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010A\"> </a>  MO010A</td><td>Osteogenic carcinoma Neoadjuvant and adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010B\"> </a>  MO010B</td><td>Relapsed Osteogenic Sarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010C\"> </a>  MO010C</td><td>Osteogenic carcinoma Neoadjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO010D\"> </a>  MO010D</td><td>Osteogenic carcinoma adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011A\"> </a>  MO011A</td><td>NACT, Adjuvant, mets (if cardiac dysfunction)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO011B\"> </a>  MO011B</td><td>Soft tissue sarcoma neoadjuvant, adjuvant and metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO012A\"> </a>  MO012A</td><td>Metastatic Melanoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO012B\"> </a>  MO012B</td><td>Metastatic Melanoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013A\"> </a>  MO013A</td><td>Stage II and III anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013B\"> </a>  MO013B</td><td>Stage II and III anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013C\"> </a>  MO013C</td><td>Metastatic Anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013D\"> </a>  MO013D</td><td>Metastatic Anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO013E\"> </a>  MO013E</td><td>Metastatic Anal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014A\"> </a>  MO014A</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014B\"> </a>  MO014B</td><td>Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014C\"> </a>  MO014C</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014D\"> </a>  MO014D</td><td>Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014E\"> </a>  MO014E</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014F\"> </a>  MO014F</td><td>Till completion of RT\nNeoadjuvant and adjuvant rectal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014G\"> </a>  MO014G</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO014H\"> </a>  MO014H</td><td>Neoadjuvant and adjuvant Colorectal Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015A\"> </a>  MO015A</td><td>Neoadjuvant and adjuvant esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015B\"> </a>  MO015B</td><td>Upper esophageal  neoadjuvant and  with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015C\"> </a>  MO015C</td><td>Upper esophageal  neoadjuvant and  with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015D\"> </a>  MO015D</td><td>With RT in definitive non-metastatic</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO015E\"> </a>  MO015E</td><td>Metastatic without RT</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016A\"> </a>  MO016A</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016B\"> </a>  MO016B</td><td>Metastatic second line esophageal and stomach cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016C\"> </a>  MO016C</td><td>Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016D\"> </a>  MO016D</td><td>Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016E\"> </a>  MO016E</td><td>Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016F\"> </a>  MO016F</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016G\"> </a>  MO016G</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016H\"> </a>  MO016H</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016I\"> </a>  MO016I</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016J\"> </a>  MO016J</td><td>Metatstaic lower esophageal and stomach Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016K\"> </a>  MO016K</td><td>Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO016L\"> </a>  MO016L</td><td>Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017A\"> </a>  MO017A</td><td>Liver confined hepatocellular carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO017B\"> </a>  MO017B</td><td>Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018A\"> </a>  MO018A</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018B\"> </a>  MO018B</td><td>Metastatic pancreatic cancer - first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018C\"> </a>  MO018C</td><td>Neoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018D\"> </a>  MO018D</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018E\"> </a>  MO018E</td><td>Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO018F\"> </a>  MO018F</td><td>Pancreatic cancer - adjuvant</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019A\"> </a>  MO019A</td><td>Adjuvant and metastatic gall bladder and cholnagicarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019B\"> </a>  MO019B</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019C\"> </a>  MO019C</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019D\"> </a>  MO019D</td><td>Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019E\"> </a>  MO019E</td><td>Metatstatic Gall Bladder Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019F\"> </a>  MO019F</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019G\"> </a>  MO019G</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO019H\"> </a>  MO019H</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020A\"> </a>  MO020A</td><td>Neoadjuvant, adjuvant and metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO020B\"> </a>  MO020B</td><td>Metastatic GIST</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO021A\"> </a>  MO021A</td><td>Adjuvant therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO021B\"> </a>  MO021B</td><td>Till RT ends\nDefinitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022A\"> </a>  MO022A</td><td>Metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022B\"> </a>  MO022B</td><td>Neoadjuvant,adjuvant and metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO022C\"> </a>  MO022C</td><td>Neoadjuvant,adjuvant and metastatic mesothelioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO023A\"> </a>  MO023A</td><td>Neoadjuvant Chemotherapy and metastatic thymic carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO023B\"> </a>  MO023B</td><td>Neoadjuvant Chemotherapy and metastatic thymic carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024A\"> </a>  MO024A</td><td>Neoadjuvant and metastatic head and neck squamou cell cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024B\"> </a>  MO024B</td><td>Definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024C\"> </a>  MO024C</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024D\"> </a>  MO024D</td><td>Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024E\"> </a>  MO024E</td><td>Metastatic squamou cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024F\"> </a>  MO024F</td><td>Metastatic Head and neck squamous cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024G\"> </a>  MO024G</td><td>Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024H\"> </a>  MO024H</td><td>Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024I\"> </a>  MO024I</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024J\"> </a>  MO024J</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024K\"> </a>  MO024K</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024L\"> </a>  MO024L</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024M\"> </a>  MO024M</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024N\"> </a>  MO024N</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024O\"> </a>  MO024O</td><td>Definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO024P\"> </a>  MO024P</td><td>Definitive therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO025A\"> </a>  MO025A</td><td>Metastatic renal cell carcinoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026A\"> </a>  MO026A</td><td>Neoadjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026B\"> </a>  MO026B</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026C\"> </a>  MO026C</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026D\"> </a>  MO026D</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026E\"> </a>  MO026E</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026F\"> </a>  MO026F</td><td>Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026G\"> </a>  MO026G</td><td>Neoadjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026H\"> </a>  MO026H</td><td>Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026I\"> </a>  MO026I</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026J\"> </a>  MO026J</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO026K\"> </a>  MO026K</td><td>Metastatic urothelial cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027A\"> </a>  MO027A</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027B\"> </a>  MO027B</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027C\"> </a>  MO027C</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027D\"> </a>  MO027D</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027E\"> </a>  MO027E</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027F\"> </a>  MO027F</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO027G\"> </a>  MO027G</td><td>Metastatic Penile Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028A\"> </a>  MO028A</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028B\"> </a>  MO028B</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028C\"> </a>  MO028C</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028D\"> </a>  MO028D</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028E\"> </a>  MO028E</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028F\"> </a>  MO028F</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028G\"> </a>  MO028G</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO028H\"> </a>  MO028H</td><td>Metastatic prostate cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO033A\"> </a>  MO033A</td><td>Multiagent chemotherapy variable in each protocol</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO047C\"> </a>  MO047C</td><td>Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO048C\"> </a>  MO048C</td><td>Optional Vincristine and Prednsiolone, intrathecal Methotrexate</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054A\"> </a>  MO054A</td><td>Histiocytosis Protocol - Induction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO054B\"> </a>  MO054B</td><td>Histiocytosis Protocol - Maintenance</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO055A\"> </a>  MO055A</td><td>Low Grade Glioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO055B\"> </a>  MO055B</td><td>Low Grade Glioma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO056A\"> </a>  MO056A</td><td>Medulloblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO056B\"> </a>  MO056B</td><td>Medulloblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO057A\"> </a>  MO057A</td><td>Neuroblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO057B\"> </a>  MO057B</td><td>Neuroblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO057C\"> </a>  MO057C</td><td>Neuroblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO058A\"> </a>  MO058A</td><td>Retinoblastoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO059A\"> </a>  MO059A</td><td>Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO059B\"> </a>  MO059B</td><td>Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO060A\"> </a>  MO060A</td><td>Relapsed Rhabdomyosarcoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO062A\"> </a>  MO062A</td><td>Phase II, CNS Therapy Reinduction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO063A\"> </a>  MO063A</td><td>Phase II, CNS Therapy Reinduction</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066A\"> </a>  MO066A</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO066B\"> </a>  MO066B</td><td>Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO067A\"> </a>  MO067A</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO067B\"> </a>  MO067B</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO067C\"> </a>  MO067C</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068A\"> </a>  MO068A</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068B\"> </a>  MO068B</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068C\"> </a>  MO068C</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO068D\"> </a>  MO068D</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071A\"> </a>  MO071A</td><td>Metstatic non small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071B\"> </a>  MO071B</td><td>Metastatic non small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071C\"> </a>  MO071C</td><td>Metastatic non small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071D\"> </a>  MO071D</td><td>Metastatic Non Small cell lung cancer - first line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071E\"> </a>  MO071E</td><td>Metastatic non small cell lung (adenocarcinoma) cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071F\"> </a>  MO071F</td><td>Metastatic small cell lung cancer - second line</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071G\"> </a>  MO071G</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071H\"> </a>  MO071H</td><td>Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071I\"> </a>  MO071I</td><td>Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071J\"> </a>  MO071J</td><td>Metastatic non small cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071K\"> </a>  MO071K</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071L\"> </a>  MO071L</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071M\"> </a>  MO071M</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071N\"> </a>  MO071N</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071O\"> </a>  MO071O</td><td>Concurrent chemoradiation in Non Small Cell lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071P\"> </a>  MO071P</td><td>Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung Cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071Q\"> </a>  MO071Q</td><td>Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071R\"> </a>  MO071R</td><td>Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071S\"> </a>  MO071S</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style=\"white-space:nowrap\"><a name=\"http---hcxprotocol.io-codes-informational-messages-codes-MO071T\"> </a>  MO071T</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr></table></div>"
  },
  "url": "https://ig.hcxprotocol.io/v0.7/ValueSet-informational-messages-codes.html",
  "version": "0.7.0",
  "name": "InformationalMessagesCodes",
  "status": "active",
  "date": "2022-06-01",
  "publisher": "HCX Open Community",
  "contact": [
    {
      "name": "HCX Open Community",
      "telecom": [
        {
          "system": "url",
          "value": "http://hcxprotocol.io/"
        }
      ]
    }
  ],
  "description": "This is the value set that includes the informational messages codes",
  "expansion": {
    "timestamp": "2022-06-01T08:15:30+05:30",
    "contains": [
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MG045A",
        "display": "Dialysis payable separately as an add on package"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MG072A",
        "display": "Package cost of one session"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MG072B",
        "display": "Package cost of one session"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MG075A",
        "display": "Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and  confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MG076A",
        "display": "Rs. 5000 is the upper limit.\nCan be booked at a lower rate also.\nIn fact the SHA should examine this package and  confirm wheter the package has been booked at the usual market rate.\nCan be booked for a pt. already admitted under any medical package."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013A",
        "display": "Stage II and III anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014F",
        "display": "Neoadjuvant and adjuvant rectal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015B",
        "display": "Upper esophageal  neoadjuvant and  with RT as adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO062A",
        "display": "ACUTE LYMPHOBLASTIC LEUKEMIA"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO062B",
        "display": "ACUTE LYMPHOBLASTIC LEUKEMIA"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO062C",
        "display": "ACUTE LYMPHOBLASTIC LEUKEMIA"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO068C",
        "display": "NON-HODGKINS LYMPHOMA"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR001A",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR001B",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR001C",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR004A",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR004B",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR004C",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR006A",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR006B",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR006C",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR009A",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR009B",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MR009C",
        "display": "The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB030A",
        "display": "Can be used for ORIF, wherever indicated.\nCan not be used as an Add - on package"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032A",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown \"For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?\" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032B",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away\nIn case Type I or II is booked a Pop Up to be shown \"For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?\" \nFor Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032C",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032D",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032E",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB032F",
        "display": "Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis\nType V & VI to be taken up for Surgery straight away"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SB070A",
        "display": "LA for - K Wire & Screw\nGA for - Nail & Plate"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SC076A",
        "display": "If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE012A",
        "display": "The package is inclusive of Eye Bank processing fee"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE012B",
        "display": "This is a special  follow up package, as in Corneal graft surgery, a follow up at 1 week is required.\nAt this time, the surgeon has to examine and then prescribe medicine for next one month.\nThe medicine for 1 month has to be given at the time of booking this package.\nA signed reciept from the pt. is an essential document"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE018A",
        "display": "To be done only after a prior scleral buckling surgery history"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE022A",
        "display": "Can be booked only after 1 year of cataract surgery"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE025A",
        "display": "Can be booked as a complication of cataract surgery atleast 15 days after discharge"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE029A",
        "display": "The procedure is done only once per eye and not repeated"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE029B",
        "display": "1. Claim to be raised after all 3 sittings have been done per eye.\n2. The interval between subsequent sittings is atleast 1 week."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SE033A",
        "display": "Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SG097A",
        "display": "Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SG097B",
        "display": "Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.\nThe Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SU052A",
        "display": "Payment to be made after completion of one month."
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SU060A",
        "display": "Claim to be raised after 6th Cycle"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SU060B",
        "display": "Claim for Rs. 15,000 can be raised after 6th Cycle.\nRemainaing Rs. 15,000 can be claimed after 12th Cycle"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SU071C",
        "display": "No payment to be done to the Hospital for this stage\nThe package can be booked only if the first stage package has been booked prior to this"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SU071D",
        "display": "The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "SV032A",
        "display": "Associated with CABG\nNeed to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included\nIncidence - 5% to 7%\nScrutiny of Hospitals where incidence is more than twice of prescribed limit"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001A",
        "display": "Adjuvant therapy in breast cancer\nMetastatic breast cancer\n(should not have received the same regimen or AC earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001B",
        "display": "Adjuvant therapy after 4 cycles of AC or EC"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001C",
        "display": "Metstatic breast cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001D",
        "display": "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy\nMetstatic breast cancer\n(should not have received the same regimen earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001E",
        "display": "Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden\nMetastatic breast cancer\n(should not have received the same regimen earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001F",
        "display": "Adjuvant therapy in breast cancer with Her-2 neu positive patients"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001G",
        "display": "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer\n(if not receive earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001H",
        "display": "Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer\nER / PR positive metastatic breast cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001I",
        "display": "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer\n(if not received earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001J",
        "display": "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001K",
        "display": "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001L",
        "display": "Adjuvant therapy in breast cancer\nMetstatic breast cancer\n(should not have received the same regimen or EC earlier)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001M",
        "display": "Metastatic  breast cancer ER / PR positive"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001N",
        "display": "Adjuvant or neoadjuvant therapy breast cancer\nmetastatic breast cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO001O",
        "display": "Metastatic breast cancer ER / PR positive"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO002A",
        "display": "Metastatic bone malignancy and multiple myeloma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003A",
        "display": "Metastatic ovarian adenocarcinoma second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003B",
        "display": "Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003C",
        "display": "Metastatic ovarian adenocarcinoma second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003D",
        "display": "Metastatic ovarian adenocarcinoma second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003E",
        "display": "Metastatic ovarian adenocarcinoma second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003F",
        "display": "Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO003G",
        "display": "Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004A",
        "display": "Testicular Seminoma, Adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004B",
        "display": "Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004C",
        "display": "Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004D",
        "display": "Germ cell tumour second line therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004E",
        "display": "Germ cell tumour second line therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004F",
        "display": "Germ cell tumour second line therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO004G",
        "display": "Germ cell tumour second line therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO005A",
        "display": "First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO005B",
        "display": "First line therapy for high - risk Gestational Trophoblastic Neoplasia\nSecond line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO005C",
        "display": "First line therapy for low risk Gestational Trophoblastic Neoplasia"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO006A",
        "display": "Neoadjuvant and metastatic Cervical Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO006B",
        "display": "Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO007A",
        "display": "Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO007B",
        "display": "Metastatic Endometrial Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO008A",
        "display": "NACT, mets"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO008B",
        "display": "Stage II and Stage III cervical cancer definitive therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO009A",
        "display": "Ewing Sarcoma second line chemotherapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO010A",
        "display": "Osteogenic carcinoma Neoadjuvant and adjuvant therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO010B",
        "display": "Relapsed Osteogenic Sarcoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO010C",
        "display": "Osteogenic carcinoma Neoadjuvant therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO010D",
        "display": "Osteogenic carcinoma adjuvant therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO011A",
        "display": "NACT, Adjuvant, mets (if cardiac dysfunction)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO011B",
        "display": "Soft tissue sarcoma neoadjuvant, adjuvant and metastatic"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO012A",
        "display": "Metastatic Melanoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO012B",
        "display": "Metastatic Melanoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013A",
        "display": "Stage II and III anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013B",
        "display": "Stage II and III anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013C",
        "display": "Metastatic Anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013D",
        "display": "Metastatic Anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO013E",
        "display": "Metastatic Anal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014A",
        "display": "Adjuvant and Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014B",
        "display": "Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014C",
        "display": "Adjuvant and Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014D",
        "display": "Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014E",
        "display": "Adjuvant and Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014F",
        "display": "Till completion of RT\nNeoadjuvant and adjuvant rectal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014G",
        "display": "Adjuvant and Metastatic Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO014H",
        "display": "Neoadjuvant and adjuvant Colorectal Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015A",
        "display": "Neoadjuvant and adjuvant esophageal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015B",
        "display": "Upper esophageal  neoadjuvant and  with RT as adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015C",
        "display": "Upper esophageal  neoadjuvant and  with RT as adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015D",
        "display": "With RT in definitive non-metastatic"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO015E",
        "display": "Metastatic without RT"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016A",
        "display": "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016B",
        "display": "Metastatic second line esophageal and stomach cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016C",
        "display": "Till RT ends\nLower esophageal and stomach Cancer with RT as adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016D",
        "display": "Till completion of RT\nLower esophageal and stomach Cancer with RT as adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016E",
        "display": "Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016F",
        "display": "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016G",
        "display": "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016H",
        "display": "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016I",
        "display": "Neoadjuvant, adjuvant and metastatic stomach and lower esophageal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016J",
        "display": "Metatstaic lower esophageal and stomach Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016K",
        "display": "Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO016L",
        "display": "Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO017A",
        "display": "Liver confined hepatocellular carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO017B",
        "display": "Meatastatic hepatocellular carcinoma (except child Pugh c)\nLiver confined but not suitable for liver directed therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018A",
        "display": "Neoadjuvant, adjuvant and metastatic pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018B",
        "display": "Metastatic pancreatic cancer - first line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018C",
        "display": "Neoadjuvant and adjuvant locally advanced pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018D",
        "display": "Neoadjuvant, adjuvant and metastatic pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018E",
        "display": "Till RT ends\nNeoadjuvant and adjuvant locally advanced pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO018F",
        "display": "Pancreatic cancer - adjuvant"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019A",
        "display": "Adjuvant and metastatic gall bladder and cholnagicarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019B",
        "display": "Neoadjuvant, adjuvant and metastatic pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019C",
        "display": "Metastatic gall bladder and cholngiocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019D",
        "display": "Till RT ends\nDefinitive and Adjuvant therapy in gall bladder cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019E",
        "display": "Metatstatic Gall Bladder Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019F",
        "display": "Neoadjuvant, adjuvant and metastatic pancreatic cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019G",
        "display": "Metastatic gall bladder and cholngiocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO019H",
        "display": "Metastatic gall bladder and cholngiocarcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO020A",
        "display": "Neoadjuvant, adjuvant and metastatic GIST"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO020B",
        "display": "Metastatic GIST"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO021A",
        "display": "Adjuvant therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO021B",
        "display": "Till RT ends\nDefinitive therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO022A",
        "display": "Metastatic mesothelioma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO022B",
        "display": "Neoadjuvant,adjuvant and metastatic mesothelioma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO022C",
        "display": "Neoadjuvant,adjuvant and metastatic mesothelioma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO023A",
        "display": "Neoadjuvant Chemotherapy and metastatic thymic carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO023B",
        "display": "Neoadjuvant Chemotherapy and metastatic thymic carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024A",
        "display": "Neoadjuvant and metastatic head and neck squamou cell cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024B",
        "display": "Definitive therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024C",
        "display": "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024D",
        "display": "Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024E",
        "display": "Metastatic squamou cell head and neck cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024F",
        "display": "Metastatic Head and neck squamous cell carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024G",
        "display": "Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024H",
        "display": "Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024I",
        "display": "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024J",
        "display": "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024K",
        "display": "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024L",
        "display": "Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024M",
        "display": "Metastatic squamous cell head and neck cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024N",
        "display": "Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024O",
        "display": "Definitive therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO024P",
        "display": "Definitive therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO025A",
        "display": "Metastatic renal cell carcinoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026A",
        "display": "Neoadjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026B",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026C",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026D",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026E",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026F",
        "display": "Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026G",
        "display": "Neoadjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026H",
        "display": "Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026I",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026J",
        "display": "Neoadjuvant, Adjuvant, Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO026K",
        "display": "Metastatic urothelial cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027A",
        "display": "Neoadjuvant, Adjuvant, Metastatic penile cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027B",
        "display": "Neoadjuvant, Adjuvant, Metastatic penile cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027C",
        "display": "Metastatic Penile Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027D",
        "display": "Neoadjuvant, Adjuvant, Metastatic penile cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027E",
        "display": "Metastatic Penile Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027F",
        "display": "Metastatic Penile Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO027G",
        "display": "Metastatic Penile Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028A",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028B",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028C",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028D",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028E",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028F",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028G",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO028H",
        "display": "Metastatic prostate cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO033A",
        "display": "Multiagent chemotherapy variable in each protocol"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO047C",
        "display": "Optional Vincristine and Prednsiolone\nIntrathecal Methotrexate"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO048C",
        "display": "Optional Vincristine and Prednsiolone, intrathecal Methotrexate"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO054A",
        "display": "Histiocytosis Protocol - Induction"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO054B",
        "display": "Histiocytosis Protocol - Maintenance"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO055A",
        "display": "Low Grade Glioma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO055B",
        "display": "Low Grade Glioma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO056A",
        "display": "Medulloblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO056B",
        "display": "Medulloblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO057A",
        "display": "Neuroblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO057B",
        "display": "Neuroblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO057C",
        "display": "Neuroblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO058A",
        "display": "Retinoblastoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO059A",
        "display": "Rhabdomyosarcoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO059B",
        "display": "Rhabdomyosarcoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO060A",
        "display": "Relapsed Rhabdomyosarcoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO062A",
        "display": "Phase II, CNS Therapy Reinduction"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO063A",
        "display": "Phase II, CNS Therapy Reinduction"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO066A",
        "display": "Relapsed Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO066B",
        "display": "Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO067A",
        "display": "Relapsed Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO067B",
        "display": "Relapsed Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO067C",
        "display": "Relapsed Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO068A",
        "display": "Non - Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO068B",
        "display": "Non - Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO068C",
        "display": "Non - Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO068D",
        "display": "Non - Hodgkins Lymphoma"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071A",
        "display": "Metstatic non small cell lung cancer - second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071B",
        "display": "Metastatic non small cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071C",
        "display": "Metastatic non small cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071D",
        "display": "Metastatic Non Small cell lung cancer - first line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071E",
        "display": "Metastatic non small cell lung (adenocarcinoma) cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071F",
        "display": "Metastatic small cell lung cancer - second line"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071G",
        "display": "Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071H",
        "display": "Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071I",
        "display": "Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071J",
        "display": "Metastatic non small cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071K",
        "display": "Neoadjuvant and Metastatic Non Small Cell Lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071L",
        "display": "Neoadjuvant and Metastatic Non Small Cell Lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071M",
        "display": "Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071N",
        "display": "Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071O",
        "display": "Concurrent chemoradiation in Non Small Cell lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071P",
        "display": "Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung Cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071Q",
        "display": "Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071R",
        "display": "Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after\nCarboplatin + Pemetrexed and\nCisplatin + Pemetrexed 4 -6 cycles"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071S",
        "display": "Neoadjuvant and Metastatic Non Small Cell Lung cancer"
      },
      {
        "system": "http://hcxprotocol.io/codes/informational-messages-codes",
        "code": "MO071T",
        "display": "Neoadjuvant and Metastatic Non Small Cell Lung cancer"
      }
    ]
  }
}